CEO Favet explains how NeuroPace is bringing neuromodulation to people with drug-resistant epilepsy
In this episode of DeviceTalks Weekly we’ll talk with Mike Favet, CEO of NeuroPace, about how the company’s RNS technology is helping to transform the lives of patients with drug-resistant epilepsy. NeuroPace, one of the pioneers in neurostimulation, has the only FDA-approved neurostim treatment for epilepsy. Favet took over as CEO four years ago from the founding CEO so we discuss his background, the changes he made at the company, and how NeuroPace is building a market for a medical device to treat a disease that typically can be managed only by pharmaceuticals.
Mike Favet will be a panelist on a keynote panel about building a neuromodulation market at DeviceTalks West on Oct. 18-19 at the Santa Clara Convention Center.
Co-hosts Tom Salemi and Chris Newmarker introduce a new formula for the Newmarker’s Newsmaker. Companies mentioned including Philips, Biotronik, Medtronic, Johnson & Johnson, GE Healthcare, Depuy Synthes, BD, and many others.
Thanks for listening to the DeviceTalks Podcast Network.
Subscribe to this network on any major podcast app.
Mike Favet will be a panelist on a keynote panel about building a neuromodulation market at DeviceTalks West on Oct. 18-19 at the Santa Clara Convention Center.
Co-hosts Tom Salemi and Chris Newmarker introduce a new formula for the Newmarker’s Newsmaker. Companies mentioned including Philips, Biotronik, Medtronic, Johnson & Johnson, GE Healthcare, Depuy Synthes, BD, and many others.
Thanks for listening to the DeviceTalks Podcast Network.
Subscribe to this network on any major podcast app.
Activity